Treatment of viral infection

a technology for viral infections and treatment, applied in the field of treatment of viral infections, can solve the problems of reducing patient compliance and complicating treatment, and achieve the effect of preventing patient complian

Pending Publication Date: 2022-03-10
ECONUGENICS
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0005]The remarkable morphological and biological similarities between gal-3 and SARS-CoV-2, particularly the spike protein thereof, make it possible to take advantage of the well- established technology focused on the administration of a safe and effective agent to the infected patient and those likely to become infected. While Pectasol-C is a preferred form of Modified Citrus Pectin (MCP) for this invention, other compositions comprising modified pectin, including modified citrus pectin, prepared by enzymatic processes or related pro

Problems solved by technology

While it is possible to use MCP of greater molecular weight, administration by IV or modes oth

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0008]Particular attention has been focused on the development of critical kidney conditions aggravated or induced by COVID-19 infection. Although no standard treatments or practices have been developed, acute kidney injury (AM) has been observed in up to twenty-five percent of patients critically ill with COVID-19 infection. Gabarre et al, Intensive Care Med., (2020). Early detection of kidney injury in these patients, and specific therapy which may be supported by reducing gal-3 levels may be critical. In a survey of over twenty-four thousand COVID-19 patients, AKI was predictive of increased severe infection and mortality rates. Shao et al, Pharmacological Research (pp. 1-12) (2020). In the absence of a new standard protocol for treatment of AKI and chronic kidney infection related to COVID-19 infection, greater attention may be focused on controlling gal-3 levels together with existing treatments such as diuretics, acetylcysteine and sodium bicarbonate may be useful. In U.S. pat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The invention is directed to the treatment of COVID-19 patients by administering to patients either infected by SARS-CoV-2 or presymptomatic for COVID-19 but at risk of severe morbidity and mortality due to potential COVID-19 infection. Such patients are given modified pectin, preferably modified citrus pectin, in an amount that may range from 2.5 or 5 on up to 10-25 grams per day, divided into two or three doses per day. The administration may be oral, by inhalation, intrabuccal or IV. The process may be combined with the administration of supportive agents like antivirals, anti-inflammatories, immune based inhibitors, vitamins, monoclonal and polyclonal anti-viral or viral binding antibodies.

Description

PRIORITY DATA AND INCORPORATION BY REFERENCE[0001]This application is related to, but does not claim priority from, U.S. Pat. Nos. 8,764,695; and 10,213,462; U.S. patent application Ser. No. 15 / 081,958 (allowed) and U.S. patent application Ser. No. 15 / 104,302. Each of these U.S. Patents and applications are incorporated herein-by-reference. Taken together, these patents clearly establish the efficacy of plasmapheresis to reduce the level in a mammal such as a human the level an agent that binds to a target also bound by circulating galectin-3 (gal-3 herein). This application is related to and claims priority from U.S. patent application Ser. No. 17 / 017,502 filed Sep. 10, 2020. The latter is directed principally to the treatment of SAR-CoV-2 infection by apheresis.BACKGROUND OF THE INVENTIONField of the Invention[0002]This invention pertains to treatment of viral infections, which may include infections from MERS, SARS, SARS-CoV-2, INFLUENZA, MEASLES, HSV I&II, HPV and other opportun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/732A61K45/06A61K31/375A61K31/59A61K39/42
CPCA61K31/732A61K45/06A61K2039/505A61K31/59A61K39/42A61K31/375
Inventor ELIAZ, ISAAC
Owner ECONUGENICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap